Arca
Skip to content
Tools
Tools

Tourette’s syndrome

Drug research and approvals for tourette’s syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 0 studies of tourette’s syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 1 approved and 9 open orphan designations naming it.

  • Recruiting worldwide: 0
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 1
  • EU medicines: 0

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 3

Phase 3 7

Phase 2 12

Phase 1 or earlier 6

How its trials ended

216 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 54 whose ending is known, 43% met their primary endpoint, 11% missed it and 46% stopped early.

  • Completed, result not reported10247%
  • Ongoing3717%
  • Met its primary endpoint2311%
  • Status unknown2311%
  • Stopped: other or unclear157%
  • Missed its primary endpoint63%
  • Stopped: enrollment or feasibility63%
  • Stopped: lack of efficacy31%
  • Stopped: funding1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
May 31, 2019A multicenter, open-label, extension study intended to evaluate the long-term safety of ecopipam tablets in children and adolescent subjects with tourette's…Ecopipam (EBS-101)Emalex Biosciences, IncClosed
May 31, 2019A multicenter, placebo-controlled, double-blind, randomized, parallel-group, phase 2b study to evaluate the efficacy and safety of ecopipam tablets in children…EcopipamEmalex Biosciences, IncClosed
Jan 17, 2019A well-controlled, fixed-dose study of TEV-50717 (deutetrabenazine) for the treatment of tics associated with tourette syndromeDeutetrabenazine (TEV-50717)Teva Pharmaceutical IndustriesPending
Apr 10, 2018An open-label, long-term safety study including a double-blind, placebo-controlled, randomized withdrawal period of TEV-50717 (deutetrabenazine) for the…Deutetrabenazine (TEV-50717)Teva Pharmaceutical IndustriesOngoing
Dec 21, 2017A randomized, double-blind, placebo-controlled study of TEV-50717 (deutetrabenazine) for the treatment of tourette syndrome in children and adolescentsDeutetrabenazine (TEV-50717)Teva Pharmaceutical IndustriesClosed
Dec 10, 2014A double-blind, randomized, placebo-controlled crossover pilot trial of medical cannabis in adults with tourette syndrome.Delta-9-tetrahydrocannabinol-cannabidiolDr Paul SandorOngoing

FDA orphan designations

Approved first, then open designations, newest first
Dec 12, 2014AbilifyTreatment of pediatric patients with Tourette'sOtsuka Pharmaceutical DevelopmentApproved
Mar 30, 2017(+)-a-dihydrotetrabenazineTreatment pediatric patients with Tourette's syndromeAdeptio Pharmaceuticals, LtdDesignated
Mar 17, 2016Guanfacine and amphetamineTreatment of pediatric patients with Tourette's syndrome (0 through 16 years of age)KemPharm, Inc.Designated
Sep 29, 2010Ecopipam hydrochlorideTreatment of pediatric patients with Tourette's syndrome.Emalex Biosciences, Inc.Designated
Jul 1, 2009TetrabenazineTreatment of Tourette's Syndrome in school-age children, ages 5-16Valeant International (Barbados) SRLDesignated
Jan 31, 2008PramipexoleTreatment of Tourette's syndrome in pediatric patientsBoehringer-Ingelheim Pharmaceuticals, Inc.Designated
Aug 26, 2003Atomoxetine hydrochlorideTreatment of Tourette's SyndromeEli Lilly & CompanyDesignated
Oct 14, 1998MecamylamineTreatment of Tourette's syndrome.Targacept, Inc.Designated
Apr 21, 1998TiaprideTreatment of Tourette's syndrome.Sanofi-Synthelabo, Inc.Designated
Nov 20, 1997PergolideTreatment of Tourette's syndrome.Sallee, Floyd R. M.D., Ph.D.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.